A Multi-center, Randomized, Double-blind, Placebo-controlled, Multiple Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneously Delivered ASLAN004 in Adults With Moderate-Severe Atopic Dermatitis

NCT04090229 · clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
52
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

ASLAN Pharmaceuticals